BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32535112)

  • 1. Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia.
    Vaikari VP; Park M; Keossayan L; MacKay JA; Alachkar H
    Nanomedicine; 2020 Oct; 29():102236. PubMed ID: 32535112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?
    Tavakkoli M; Chung SS; Park CY
    Expert Opin Ther Targets; 2018 May; 22(5):381-383. PubMed ID: 29637789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-FLT3 nanoparticles for acute myeloid leukemia: Preclinical pharmacology and pharmacokinetics.
    Park M; Vaikari VP; Lam AT; Zhang Y; MacKay JA; Alachkar H
    J Control Release; 2020 Aug; 324():317-329. PubMed ID: 32428520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.
    Shi J; Zhang Z; Cen H; Wu H; Zhang S; Liu J; Leng Y; Ren A; Liu X; Zhang Z; Tong X; Liang J; Li Z; Zhou F; Huang L; Qin Y; Yang K; Zhang T; Zhu H
    J Hematol Oncol; 2021 Oct; 14(1):162. PubMed ID: 34627328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD99 is a therapeutic target on disease stem cells in myeloid malignancies.
    Chung SS; Eng WS; Hu W; Khalaj M; Garrett-Bakelman FE; Tavakkoli M; Levine RL; Carroll M; Klimek VM; Melnick AM; Park CY
    Sci Transl Med; 2017 Jan; 9(374):. PubMed ID: 28123069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma.
    Takheaw N; Sittithumcharee G; Kariya R; Kasinrerk W; Okada S
    Cancer Immunol Immunother; 2021 Jun; 70(6):1557-1567. PubMed ID: 33215253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-valency Anti-CD99 Antibodies Toward the Treatment of T Cell Acute Lymphoblastic Leukemia.
    Romero LA; Hattori T; Ali MAE; Ketavarapu G; Koide A; Park CY; Koide S
    J Mol Biol; 2022 Mar; 434(5):167402. PubMed ID: 34958778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
    Hutmacher C; Volta L; Rinaldi F; Murer P; Myburgh R; Manz MG; Neri D
    Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia.
    Vaikari VP; Du Y; Wu S; Zhang T; Metzeler K; Batcha AMN; Herold T; Hiddemann W; Akhtari M; Alachkar H
    Haematologica; 2020 Apr; 105(4):999-1012. PubMed ID: 31371417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoreactivity of MIC2 (CD99) in acute myelogenous leukemia and related diseases.
    Zhang PJ; Barcos M; Stewart CC; Block AW; Sait S; Brooks JJ
    Mod Pathol; 2000 Apr; 13(4):452-8. PubMed ID: 10786814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
    Herrmann M; Krupka C; Deiser K; Brauchle B; Marcinek A; Ogrinc Wagner A; Rataj F; Mocikat R; Metzeler KH; Spiekermann K; Kobold S; Fenn NC; Hopfner KP; Subklewe M
    Blood; 2018 Dec; 132(23):2484-2494. PubMed ID: 30275109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.
    Habibi-Anbouhi M; Kafi Z; Ghazizadeh L; Kharazi S; Behdani M; Faraji F; Shokrgozar MA
    Iran J Allergy Asthma Immunol; 2019 Oct; 18(6):679-687. PubMed ID: 32245312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CHMP5 single chain variable fragment antibody retrovirus infection induces programmed cell death of AML leukemic cells in vitro.
    Wang HR; Xiao ZY; Chen M; Wang FL; Liu J; Zhong H; Zhong JH; Ou-Yang RR; Shen YL; Pan SM
    Acta Pharmacol Sin; 2012 Jun; 33(6):809-16. PubMed ID: 22609838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes.
    Kang LC; Dunphy CH
    Arch Pathol Lab Med; 2006 Feb; 130(2):153-7. PubMed ID: 16454553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
    Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling.
    Manara MC; Terracciano M; Mancarella C; Sciandra M; Guerzoni C; Pasello M; Grilli A; Zini N; Picci P; Colombo MP; Morrione A; Scotlandi K
    Oncotarget; 2016 Nov; 7(48):79925-79942. PubMed ID: 27835596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia.
    Zheng B; Yu SF; Del Rosario G; Leong SR; Lee GY; Vij R; Chiu C; Liang WC; Wu Y; Chalouni C; Sadowsky J; Clark V; Hendricks A; Poon KA; Chu W; Pillow T; Schutten MM; Flygare J; Polson AG
    Clin Cancer Res; 2019 Feb; 25(4):1358-1368. PubMed ID: 29959143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
    Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
    Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
    [No Abstract]   [Full Text] [Related]  

  • 19. Triggering of CD99 on monocytes by a specific monoclonal antibody regulates T cell activation.
    Laopajon W; Pata S; Takheaw N; Surinkaew S; Khummuang S; Kasinrerk W
    Cell Immunol; 2019 Jan; 335():51-58. PubMed ID: 30396687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.
    Powell JA; Lewis AC; Zhu W; Toubia J; Pitman MR; Wallington-Beddoe CT; Moretti PA; Iarossi D; Samaraweera SE; Cummings N; Ramshaw HS; Thomas D; Wei AH; Lopez AF; D'Andrea RJ; Lewis ID; Pitson SM
    Blood; 2017 Feb; 129(6):771-782. PubMed ID: 27956387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.